Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 22 May 2017, 11:00 HKT/SGT

Source: Singapore eDevelopment Ltd
Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform
- Nobel Prize nominee Daryl Thompson to lead research, conducted by subsidiary Global BioLife Inc., supported by Charles River Laboratories
- Six month target for validating lab data, twelve month target for completion of platform

SINGAPORE, May 22, 2017 - (ACN Newswire) - Singapore eDevelopment Ltd ("SeD"), through subsidiary Global BioLife Inc. ("Global BioLife"), has initiated advanced research on a new universal therapeutic drug platform known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee Mr Daryl Thompson.

SGX-listed SeD (SP:SGE) said Mr Thompson would leverage his expertise in organic and carbohydrate chemistry and the use of pandemic technology in combating the Ebola virus in the development of Linebacker. Unlike traditional approaches to curing individual diseases with specific drugs, the Linebacker platform seeks a breakthrough option for multiple diseases to be cured. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.

Mr Thompson will lead the research, to be conducted by Global BioLife, in his capacity as Director of Scientific Initiatives. Global BioLife is an 80%-held subsidiary of SeD's wholly-owned subsidiary, Global BioMedical Inc. The remaining stake in Global BioLife is held in equal proportions by Mr Thompson's GRDG Sciences LLC and ASX-listed Holista CollTech Limited.

Mr Thompson was nominated for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his expertise to initiate research regarding universal therapeutics to cure the world's deadliest diseases. Mr Scott Truesdell, Research Coordinator and Special Projects Leader at Global BioLife, will execute the research on the Linebacker platform.

Global BioLife has engaged NYSE-listed Charles River Laboratories International, Inc., which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Mr Thompson said, "We expect to obtain validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be completed within twelve months. We have a unique patented technology and are already getting interest from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available."

"Global BioLife recognizes the need for affordable cures to emerging pandemics and we will leverage the team's deep expertise to develop this new universal therapeutic drug platform," said Dr Tang Peihong, Global BioLife Director and CEO. Dr Tang has a Ph.D. in Chemical Engineering and was selected as National Distinguished Expert in China's Thousand Talents Plan in 2012.

GRDG Sciences LLC is a natural products discovery drug research company formed in Florida, USA by Mr Thompson, a natural products scientist. GRDG Sciences works with multiple global institutions such as Charles River. Holista CollTech Ltd is a research-driven biotech company that resulted from the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. It is dedicated to delivering first-class natural ingredients and wellness products (

About Singapore eDevelopment Limited

Incorporated on 9 September 2009, and listed on the Singapore Exchange Catalist (SGX:40V) in July 2010 (SP: SGE; SINE), Singapore eDevelopment is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) Information Technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit:

Issued on behalf of the Company:
WeR1 Consultants Pte Ltd
Mr Ian Lau
T: +65 6737 4844
Singapore 048693

May 22, 2017 11:00 HKT/SGT
Topic: General Announcement
Sectors: Investors/Exchanges, Daily Finance, BioTech, HealthCare, Alternatives
From the Asia Corporate News Network

Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Singapore eDevelopment Ltd
June 12, 2019 14:00 HKT/SGT
Global BioLife's new mosquito repellent formula performs well against mosquitos in independent testing
Jan 28, 2019 12:00 HKT/SGT
Singapore eDevelopment subsidiary Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
Nov 7, 2018 19:00 HKT/SGT
Singapore eDevelopment Subsidiary, Global BioLife, Proudly Announces Presentation of Parkinson's Research at Neuroscience 2018
June 18, 2018 19:00 HKT/SGT
Singapore eDevelopment Announces Corporate and Business Update
May 31, 2018 18:00 HKT/SGT
Singapore Exchange-Listed Singapore eDevelopment Limited's U.S. Biomedical Subsidiary Global BioLife, Inc. Develops Low Glycemic Modified Sugar
Mar 1, 2018 14:00 HKT/SGT
Singapore eDevelopment biomedical subsidiary confirms LB2 efficacy against Ebola
Nov 1, 2017 18:00 HKT/SGT
Singapore eDevelopment's Biomedical Subsidiary Confirms 100% Repellency of 3F Mosquito Fragrance
Oct 24, 2017 18:00 HKT/SGT
SGX-Listed Singapore eDevelopment's Global BioLife Inc Develops Breakthrough Modified Sugar
Aug 15, 2017 19:00 HKT/SGT
Singapore eDevelopment's Global BioLife and U.S.-based Chemia Corporation to Develop Functional Fragrances to Fight Mosquito-Borne Diseases
June 15, 2017 10:15 HKT/SGT
First-Year Performance of Global Systematic Multi-Strategy Fund
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: